Eton Pharmaceuticals (ETON) News Today $14.41 +0.13 (+0.91%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Eton Pharmaceuticals, Inc. (ETON): Analysts Recommend This 52-Week High Stocks NowJanuary 15 at 6:47 PM | msn.comResearch Analysts Offer Predictions for ETON Q1 EarningsJanuary 14 at 2:07 AM | americanbankingnews.comTop 5 Small-cap Pharma Stocks (Updated January 2025)January 13, 2025 | msn.comEton Pharmaceuticals (NASDAQ:ETON) Earns Buy Rating from Analysts at B. RileyJanuary 13, 2025 | americanbankingnews.comQ1 Earnings Estimate for ETON Issued By B. RileyEton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Eton Pharmaceuticals in a research report issued on Thursday, January 9th. B. Riley analyst M. El-Saadi anticipates that the company will post earnings of $0.03 per shareJanuary 13, 2025 | marketbeat.comEton Pharmaceuticals (NASDAQ:ETON) Raised to "Strong-Buy" at B. RileyB. Riley raised Eton Pharmaceuticals to a "strong-buy" rating in a research note on Thursday.January 11, 2025 | marketbeat.comCraig Hallum Increases Eton Pharmaceuticals (NASDAQ:ETON) Price Target to $18.00January 11, 2025 | americanbankingnews.comB. Riley Securities Initiates Coverage of Eton Pharmaceuticals (ETON) with Buy RecommendationJanuary 11, 2025 | msn.comEton Pharmaceuticals: Strategic Acquisitions and Growth Prospects Drive Buy RatingJanuary 10, 2025 | markets.businessinsider.comEton Pharmaceuticals initiated with a Buy at B. RileyJanuary 10, 2025 | markets.businessinsider.comB. Riley Initiates Coverage on Eton Pharmaceuticals (NASDAQ:ETON)B. Riley started coverage on shares of Eton Pharmaceuticals in a report on Friday. They issued a "buy" rating and a $21.00 price objective on the stock.January 10, 2025 | marketbeat.comQ2 EPS Estimate for Eton Pharmaceuticals Raised by AnalystJanuary 10, 2025 | americanbankingnews.comInvesting in Eton Pharmaceuticals (NASDAQ:ETON) three years ago would have delivered you a 177% gainJanuary 9, 2025 | finance.yahoo.comResearch Analysts Issue Forecasts for ETON Q2 EarningsEton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Research analysts at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for Eton Pharmaceuticals in a report released on Monday, January 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will postJanuary 9, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for ETON FY2027 Earnings?January 9, 2025 | americanbankingnews.comCraig-Hallum Keeps Their Buy Rating on Eton Pharmaceuticals (ETON)January 8, 2025 | markets.businessinsider.comEton Pharmaceuticals price target raised to $18 from $15 at Craig-HallumJanuary 8, 2025 | markets.businessinsider.comThe Analyst Verdict: Eton Pharmaceuticals In The Eyes Of 5 ExpertsJanuary 8, 2025 | benzinga.comEton Pharmaceuticals (NASDAQ:ETON) Price Target Raised to $18.00 at Craig HallumCraig Hallum boosted their price target on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a "buy" rating in a research report on Wednesday.January 8, 2025 | marketbeat.comHC Wainwright Issues Optimistic Estimate for ETON EarningsEton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Stock analysts at HC Wainwright increased their FY2027 earnings estimates for Eton Pharmaceuticals in a research note issued to investors on Monday, January 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post eaJanuary 8, 2025 | marketbeat.comRepare Therapeutics (NASDAQ:RPTX) vs. Eton Pharmaceuticals (NASDAQ:ETON) Financial SurveyJanuary 8, 2025 | americanbankingnews.comEton Pharmaceuticals (NASDAQ:ETON) Given New $17.00 Price Target at HC WainwrightJanuary 7, 2025 | americanbankingnews.comStrategic Acquisition of Galzin Boosts Eton Pharmaceuticals’ Long-Term Growth Prospects and Raises Price TargetJanuary 6, 2025 | markets.businessinsider.comEton Pharmaceuticals price target raised to $17 from $15 at H.C. WainwrightJanuary 6, 2025 | markets.businessinsider.comEton Pharmaceuticals (NASDAQ:ETON) Price Target Raised to $17.00HC Wainwright increased their price target on shares of Eton Pharmaceuticals from $15.00 to $17.00 and gave the company a "buy" rating in a report on Monday.January 6, 2025 | marketbeat.comEton Pharmaceuticals acquires GalzinJanuary 3, 2025 | markets.businessinsider.comEton acquires Wilson disease drug GalzinJanuary 3, 2025 | msn.comEton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®January 3, 2025 | finance.yahoo.comEton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®January 3, 2025 | globenewswire.comEton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)December 20, 2024 | finance.yahoo.comEton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)December 20, 2024 | globenewswire.comEton Pharma Announces Final Readout Of PKU GOLIKE StudyDecember 17, 2024 | markets.businessinsider.comEton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical TrialDecember 17, 2024 | finance.yahoo.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Sees Significant Increase in Short InterestEton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) saw a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 273,900 shares, an increase of 32.6% from the November 15th total of 206,500 shares. Currently, 1.1% of the company's shares are short sold. Based on an average daily volume of 219,900 shares, the days-to-cover ratio is presently 1.2 days.December 15, 2024 | marketbeat.comCraig-Hallum Remains a Buy on Phathom Pharmaceuticals (PHAT)December 12, 2024 | markets.businessinsider.comEton Pharmaceuticals, Inc.'s (NASDAQ:ETON) top owners are retail investors with 58% stake, while 26% is held by institutionsDecember 12, 2024 | uk.finance.yahoo.comAngitia Biopharmaceuticals Announces $120 Million Series C FinancingDecember 11, 2024 | finance.yahoo.comEton Pharmaceuticals (ETON) Receives a Buy from Craig-HallumDecember 6, 2024 | markets.businessinsider.comEton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial OfficerDecember 3, 2024 | globenewswire.com238,565 Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Acquired by Wasatch Advisors LPWasatch Advisors LP purchased a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 238,565 shares of the company's stock, valued at approximately $1,43December 2, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for ETON FY2024 Earnings?Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Investment analysts at HC Wainwright reduced their FY2024 EPS estimates for shares of Eton Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 26th. HC Wainwright analyst S. Ramakanth now anticipates thNovember 28, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for ETON Q1 Earnings?Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Stock analysts at HC Wainwright decreased their Q1 2025 earnings per share (EPS) estimates for shares of Eton Pharmaceuticals in a note issued to investors on Tuesday, November 26th. HC Wainwright analyst S. Ramakanth now forecasts that theNovember 27, 2024 | marketbeat.comEton acquires US rights to neonatal diabetes treatment from AMMTeKNovember 26, 2024 | msn.comEton Pharma - Small Cap That's ClimbingNovember 26, 2024 | msn.comEton Pharmaceuticals price target raised to $15 from $11 at H.C. WainwrightNovember 26, 2024 | markets.businessinsider.comEton Pharmaceuticals (NASDAQ:ETON) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $15.00 price target (up previously from $11.00) on shares of Eton Pharmaceuticals in a report on Tuesday.November 26, 2024 | marketbeat.comEton Pharmaceuticals acquires U.S. rights to Amglidia from AMMTeKNovember 25, 2024 | markets.businessinsider.comEton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)November 25, 2024 | globenewswire.comShort Interest in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Drops By 6.2%Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) was the recipient of a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 191,900 shares, a decrease of 6.2% from the October 15th total of 204,600 shares. Based on an average daily trading volume, of 156,700 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.8% of the company's shares are short sold.November 18, 2024 | marketbeat.comHC Wainwright Has Bullish Forecast for ETON FY2024 EarningsEton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Analysts at HC Wainwright upped their FY2024 earnings per share estimates for shares of Eton Pharmaceuticals in a research report issued on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earNovember 18, 2024 | marketbeat.com Get Eton Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter. Email Address ETON Media Mentions By Week ETON Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ETON News Sentiment▼0.800.72▲Average Medical News Sentiment ETON News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ETON Articles This Week▼143▲ETON Articles Average Week Get Eton Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TVTX News VIR News GPCR News XNCR News SDGR News ARDX News NRIX News KNSA News OCUL News RCUS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ETON) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eton Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eton Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
